Wed, Jul 23, 2014, 5:41 AM EDT - U.S. Markets open in 3 hrs 49 mins


% | $
Click the to save as a favorite.

InVivo Therapeutics Holdings Corp. Message Board

factman777 3 posts  |  Last Activity: Jun 24, 2014 5:29 PM Member since: Oct 10, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • factman777 factman777 Jun 24, 2014 5:29 PM Flag

    Looks like MR. Perrin is also recognizing the hard work as Mr. Astrue did. The January 1, 2014 press release stated the following:

    "InVivo Therapeutics Holdings Corp. (NVIV) today announced the promotion of Lisa Crockett to Vice President, Regulatory and Kristin Neff to Vice President, Clinical Operations. These promotions are effective January 1, 2014.

    Interim Chief Executive Officer Michael Astrue said, “These two executives have been instrumental in our effort to put our first product candidate into the clinic in the next few months. They have both also demonstrated expertise and judgment with their work on InVivo’s evolving pipeline.”

    Sentiment: Strong Buy

  • It would take another company a decade and a ton of R&D money to get to where InVivo is today. Think about all the animal studies that have to be performed and even more difficult to get the Human clinical trials approved by our snail-moving FDA. So why are we selling for $1.01? Simple... its because of the replacement of the former CEO (who told several lies by omission) and some typical delays when doing business in the bio-tech field. Delays in the bio-tech field are part of the norm but they provide the bashes with ample ammunition to drive a stock price down.

    However, everything is now in place. All systems are now a go with plenty of cash to see the human clinical trials through.

    By the way: Lying by omission is when an important fact is omitted, deliberately leaving another person with a misconception. This includes failures to correct pre-existing misconceptions. Frank Reynolds was very good at lying by omission and misleading the shareholders.

    Michael Astrue,a man of high integrity who turned around InVivo and told the shareholders the truth, handpicked Mark Perrin to be the new CEO so I am confident going forward. Mr. Astrue also took his outgoing bonus in shares of InVivo instead of cash.

    The more I think about it the more I like the risk/reward going forward...

    Sentiment: Strong Buy

  • It was obvious that the Hydrogel platform was another pipe dream from the former CEO Frank Reynolds. That why the Investor Relation presentation from May 2, 2014 had only 3 of the 51 pages about Hydrogel. (Note: the presentation has been updated as of today). The company is now laser focused on the Neuro-Spinal Scaffold human clinical trials which can enroll their first patient anytime now and the company now has existing funds through March 2016. Also, the 7 million warrants at $1.43 that will bring in an additional $10 million dollars down the road.

    Don’t forget that this is an open label clinical trial so results can be reported during the trial of each patient. If even 10% of the nerve tissue can be preserved, it can make a world of difference to the patient’s outcome and quality of life. Even something so small as a patient who is totally paralyzed vs. one who can move a finger to press buttons on a wheel chair is a huge difference … let alone walk across the room as all the African Green monkeys could afterwards.

    Remember, NVIV has tested over 40 paralyzed African Green monkeys and every one of them was able to run again within 3 weeks. These monkeys are excellent models for humans with a genomic similarity in excess of 98%, and the neuro-physiological characteristics of how the spinal cord works in humans as compared to these African Green monkeys is nearly identical.

    I like the risk/reward going forward…

    Sentiment: Strong Buy

1.01-0.02(-1.94%)Jul 22 3:35 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.